Cue Biopharma, Inc.
CUE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | 0.04 | -0.04 | 0.09 |
| FCF Yield | -12.45% | -5.28% | -12.30% | -11.16% |
| EV / EBITDA | -9.18 | -5.93 | -5.48 | -7.28 |
| Quality | ||||
| ROIC | -38.47% | -33.23% | -89.74% | -36.52% |
| Gross Margin | 96.32% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.21 | 0.40 | 0.67 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.95% | 66.73% | 164.47% | 95.39% |
| Free Cash Flow Growth | -162.17% | 58.64% | 7.84% | -19.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.76 | 2.60 | 0.53 | 1.47 |
| Interest Coverage | -100.59 | -191.89 | -96.09 | -62.96 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,579.20 | 16.21 | 0.00 | 53.97 |